VALIANT

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
DTC, Safety, Creatinine, VALIANT, Swedish Orphan Biovitrum, MAA, CHMP, Justice, Insurance, Webcast, Administration, Patient, CJEU, CAD, EMA, Cold agglutinin disease, Judgement, Standard of care, PNH, APLS, European Medicines Agency, Injection, Ageing, Pharmaceutical industry

ET

Key Points: 
  • ET
    WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights.
  • EMPAVELI for the treatment of PNH:
    Generated $25.6 million in EMPAVELI U.S. net product revenue in the first quarter of 2024.
  • Apellis reported a net loss of $66.4 million for the first quarter 2024, compared to a net loss of $177.8 million for the same period in 2023.
  • Apellis will host a conference call and webcast to discuss its first quarter 2024 financial results and business highlights today, May 7, 2024, at 8:30 a.m.

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
火曜日, 2月 27, 2024
PEGASUS, Quarter, EMA, Committee, ALS, APLS, Recurrence, AAO, ASH, Note, Physician, FDA, Marketing, Data, Treasury, Safety, CAD, Society, VALIANT, Cold agglutinin disease, CHMP, European Medicines Agency, Administration, Patient, Public expenditure, Webcast, GALE, PRINCE, PNH, ASN, Research, Travel, American Academy, Pharmaceutical industry

Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.

Key Points: 
  • Cost of sales was $19.9 million for the fourth quarter of 2023, compared to $2.9 million for the fourth quarter of 2022, respectively.
  • R&D expenses were $69.3 million for the fourth quarter of 2023, compared to $99.4 million for the fourth quarter of 2023.
  • G&A expenses were $141.7 million for the fourth quarter of 2023, compared to $84.4 million for the fourth quarter of 2022.
  • Apellis will host a conference call and webcast to discuss its fourth quarter and year end 2023 financial results and business highlights today, February 27, 2024, at 8:30 a.m.

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients

Retrieved on: 
木曜日, 3月 7, 2024
Health, Other Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, EOS, TSLP, Polyp (medicine), Sinusitis, Inflammation, Upstream, Asthma, Biomarker, VALIANT, Patient, Clinical trial, Tezepelumab, Nitric acid, Pharmaceutical industry

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in its Phase 2 VALIANT clinical trial of verekitug (UPB-101) in patients with severe asthma.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in its Phase 2 VALIANT clinical trial of verekitug (UPB-101) in patients with severe asthma.
  • Verekitug is a recombinant fully human immunoglobulin G1 monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation.
  • Verekitug is currently under investigation in a Phase 2 study for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
  • The study will evaluate verekitug’s efficacy in the treatment of severe asthma as reflected by the registrational primary endpoint of the annual asthma exacerbation rate (AAER).

"AUTHOR BRENDA M LANE TAKES READERS ON AN EMOTIONAL JOURNEY … I FOUND THIS BOOK HARD TO PUT DOWN." - Literary Titan

Retrieved on: 
火曜日, 1月 9, 2024
MUSIC, Budapest Symphony Orchestra, Faith, Intense, Inspirational fiction, Life, Friends, Publishing, Composer, VALIANT, Book, NOTE, Choir, NOW, Star Trek, Marginal, Amazing, News, Happiness

CHICO, Calif., Jan. 9, 2024 /PRNewswire-PRWeb/ -- Debuting her first Inspirational Fiction, Marginal Madge Always on the Edge, (12-18+age category), Lane says, "Unlike my non-fiction books that are filled with unvarnished truth, this was my first attempt at Inspirational Fiction. Marginal Madge Always on the Edge, was a genuinely fun book to write! The story was vaguely based on the life of one of my friends, who has always intrigued me with her calm/funny participation in life. I took what was a foundation for the story and turned it into a whimsical account of circumstances, steering it straight into the Happy place."

Key Points: 
  • Lane & Associated Enterprises Publishing is announcing a double boon for Author, Brenda M Lane in both BOOK and MUSIC categories!
  • The story was vaguely based on the life of one of my friends, who has always intrigued me with her calm/funny participation in life.
  • I took what was a foundation for the story and turned it into a whimsical account of circumstances, steering it straight into the Happy place."
  • Professionally narrated by British voice-over actress, Judith Bareham, the book took on a unique and delightfully warm familiarity!

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

Retrieved on: 
水曜日, 11月 1, 2023
FDA, Insurance, United Kingdom, CAD, PNH, Ophthalmology, Proteinuria, Injector, Congress, Workforce, European Medicines Agency, Research, R, Society, American Society of Nephrology, VALIANT, Growth, Clinical trial, American Academy, GA, Swedish Orphan Biovitrum, Recurrence, Webcast, ASN, U.S. FDA, Cold agglutinin disease, Travel, Safety, Patient, Administration, GALE, Lancet, APLS, Video game, Rare-earth element, Pharmaceutical industry, Clothing, Medical device, Beauty salon, OAKS, G&A, EU

Delivered approximately 37,000 commercial vials and 10,000 samples of SYFOVRE to physician practices in the third quarter 2023.

Key Points: 
  • Delivered approximately 37,000 commercial vials and 10,000 samples of SYFOVRE to physician practices in the third quarter 2023.
  • EMPAVELI for the treatment of PNH:
    Generated $23.9 million in EMPAVELI U.S. net product revenue in the third quarter 2023.
  • In August 2023, Apellis announced a corporate restructuring to drive growth of SYFOVRE and EMPAVELI, positioning Apellis for long-term success.
  • Apellis will host a conference call and webcast to discuss its third quarter 2023 financial results and business highlights today, November 1, 2023, at 8:00 a.m.

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

Retrieved on: 
火曜日, 10月 17, 2023
EGFR, APLS, Biomarker, Inflammation, Columbia University Irving Medical Center, Kidney failure, Society, Week, Columbia University, Recurrence, Disease, Kidney, ASN, Proteinuria, VALIANT, Rare, Adolescence, Poster, Glomerular filtration rate, American Society of Nephrology, Patient, Medical device, Pharmaceutical industry

The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan.

Key Points: 
  • The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan.
  • Five (50%) patients showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline.
  • Excessive deposition of C3 breakdown products in the kidney leads to inflammation and damage of the kidney, often causing kidney failure.
  • Data from the Phase 2 DISCOVERY study investigating pegcetacoplan in patients with C3G in native kidneys was recently published in KI Reports .

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

Retrieved on: 
火曜日, 8月 29, 2023
Workforce, Retina, Central nervous system, APLS, European Medicines Agency, Research, CNS, Small RNA, EMA, Beam Therapeutics, VALIANT, Patient, Kidney, PNH, United Kingdom, Growth, Therapy, Vaccine, Pharmaceutical industry, Nursing, EU

We are thankful for the commitment and contributions of our colleagues who have worked relentlessly to advance life-changing medicines for some of the most challenging diseases patients face.

Key Points: 
  • We are thankful for the commitment and contributions of our colleagues who have worked relentlessly to advance life-changing medicines for some of the most challenging diseases patients face.
  • On August 22, the Company reported that over 26,000 vials had been distributed in the third quarter.
  • The Company is preparing to launch SYFOVRE in the EU, prioritizing an initial launch in Germany.
  • The Company will provide an update on its expected cash runway in connection with its third quarter 2023 earnings update.

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
月曜日, 7月 31, 2023
Retina, Prescription Drug User Fee Act, ALS, Swedish Orphan Biovitrum, Travel, APLS, Week, AMD, GALE, Retinal vasculitis, European Medicines Agency, Clinical trial, CAD, Cold agglutinin disease, Research, GA, Patient safety, DSM-IV codes, C3, VALIANT, Patient, Administration, PNH, PDUFA, Webcast, United Kingdom, R, FDA, Society, Safety, Pharmaceutical industry, Sewage treatment, Clothing, Vaccine, Medical device, Video game, EU, G&A

EMPAVELI for the treatment of PNH:

Key Points: 
  • EMPAVELI for the treatment of PNH:
    Apellis reported $22.3 million in EMPAVELI U.S. net product revenue for the second quarter 2023.
  • Cost of sales were $8.4 million for the second quarter 2023, compared to $0.1 million for same period in 2022.
  • Apellis reported a net loss of $122.0 million for the second quarter 2023, compared to a net loss of $156.0 million for the same period in 2022.
  • Apellis will host a conference call and webcast to discuss its second quarter 2023 financial results and business highlights today, July 31, 2023, at 8:30 a.m.

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

Retrieved on: 
木曜日, 5月 4, 2023
Retina, Prescription Drug User Fee Act, ALS, Travel, Swedish Orphan Biovitrum, APLS, Stargardt disease, AMD, European Medicines Agency, Clinical trial, CAD, Geographic atrophy, Stargardt, Cold agglutinin disease, Research, GA, DSM-IV codes, C3, VALIANT, VEGF, Shanda, Patient, Physician, Data, Administration, PEGASUS, PNH, PDUFA, Webcast, United Kingdom, R, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Mobile phone, Pharmaceutical industry, Nursing, Sewage treatment, Video game, Medical device, EU, Health, G&A, OAKS

EMPAVELI for the treatment of PNH:

Key Points: 
  • EMPAVELI for the treatment of PNH:
    Apellis recorded $20.4 million in EMPAVELI U.S. net product revenue for the first quarter 2023.
  • Cost of sales were $7.8 million for the first quarter 2023, compared to $1.2 million for same period in 2022.
  • Apellis reported a net loss of $177.8 million for the first quarter 2023, compared to a net loss of $138.9 million for the same period in 2022.
  • Apellis will host a conference call and webcast to discuss its first quarter 2023 financial results and business highlights today, May 4, 2023, at 4:30 p.m.

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
火曜日, 2月 21, 2023
APLS, C3, European Commission, Cold agglutinin disease, Standard of care, Prescription Drug User Fee Act, United Kingdom, ALS, Shanda, PEGASUS, PDUFA, Safety, AMD, Administration, GA, Patient, Small RNA, Health Canada, Clinical trial, RNA, PNH, University, Research, European Medicines Agency, DSM-IV codes, Quarter, OAKS, VEGF, Beam, EC, FDA, CAD, EU, Swedish Orphan Biovitrum, VALIANT, R, Geographic atrophy, IND, Medical device, Video game, Pharmaceutical industry, Sewage treatment, Cryptocurrency, G&A

EMPAVELI for the treatment of PNH:

Key Points: 
  • EMPAVELI for the treatment of PNH:
    Apellis recorded $19.7 million and $65.1 million in EMPAVELI U.S. net product revenue for the fourth quarter and full year 2022, respectively.
  • Fourth Quarter and Full Year 2022 Financial Results:
    Cash.
  • R&D expenses were $99.4 million for the fourth quarter of 2022, compared to $108.2 million for the same period in 2021.
  • G&A expenses were $84.4 million for the fourth quarter of 2022, compared to $41.5 million for the same period in 2021.